Weekly Bortezomib/Methylprednisolone is Effective and Well Tolerated in Relapsed Multiple Myeloma
Authors:
- Gina G. SmithGSGina G. Smith
- Beth E. JuliarBJBeth E. Juliar
- Rafat AbonourRARafat Abonour
- 1 September 2006
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 7 (2) , 131-134
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Systemic Corticosteroid Therapy for Acute Asthma ExacerbationsJournal of Asthma, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaBritish Journal of Haematology, 2005
- A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced CancerClinical Cancer Research, 2005
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood, 2005
- Bortezomib: A valuable new antineoplastic strategy in multiple myelomaActa Oncologica, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004
- A high-dose pulse steroid regimen for controlling active chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2001